Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma Therapy in Patients With COVID-19
NCT04407208Phase 1Completed
- Sponsor
- Biofarma
- Start
- May 2020
- Primary completion
- Jun 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19), sponsored by Biofarma. Primary endpoints: Plaque Reduction Neutralization Test at Day 7, D-dimer at Day 14 and 4 more. Started May 2020; status: completed.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04407208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04407208.